1-6 of 6
Andrew Stefka
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)

Ben A. Derman, Ajay Major, Sarah Major, Brittany D. Wolfe, Martha Gorski, Jennifer H. Cooperrider, Evangelia Andreatos, Ken Jiang, Karson Buckley, Amanda McIver, Andrew Stefka, Andrzej Jakubowiak
Journal: Blood
Blood (2022) 140 (Supplement 1): 2108–2109.
https://doi.org/10.1182/blood-2022-158643
Published: 2022
Journal Articles

A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma

Ben A Derman, Ajay Major, Jacalyn Rosenblatt, David Avigan, Murtuza M. Rampurwala, Luis Alcantar, Bernadette M. Libao, Amanda McIver, Evangelia Andreatos, Sarah Major, Brittany Wolfe, Martha Gorski, Theodore G. Karrison, Andrew Stefka, Andrzej Jakubowiak
Journal: Blood
Blood (2021) 138 (Supplement 1): 2759.
https://doi.org/10.1182/blood-2021-151832
Published: 2021
Journal Articles

Daratumumab (DARA) Plus Carfilzomib, Pomalidomide, Dexamethasone (KPd) in Lenalidomide Refractory Multiple Myeloma (MM): A Multi-Center MMRC Study

Jagoda Jasielec, MD, Jeff Zonder, MD, Benjamin A Derman, MD, Donna E. Reece, MD, Craig E. Cole, MD, Jesus G. Berdeja, MD, Brittany Wolfe, Sarah Major, Kathryn M. Tinari, Andrew Stefka, MS, Fabrizio Fazzi, Megan Whelan, Christine Gleason, Amanda McIver, Evangelia Andreatos, Bernadette M. Libao, Daniel Juergens, Kent Griffith, Andrzej Jakubowiak, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50.
https://doi.org/10.1182/blood-2020-141029
Published: 2020
Journal Articles

High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Andrzej J. Jakubowiak, MD, Noopur Raje, MD, Ravi Vij, MDMBA, Donna Reece, MD FRCP(C), Jesus G. Berdeja, MD, Leonor Stephens, Kathryn M. Tinari, Cara A. Rosenbaum, Jagoda K. Jasielec, Paul G Richardson, MD, Sandeep Gurbuxani, Jennifer Nam, Erica Severson, Amanda McIver, Brittany Wolfe, Sarah Major, Shaun Rosebeck, Andrew Stefka, MS, David Johnson, Dominik Dytfeld, Kent Griffith, Agata Turowski, Tyler Hycner, Todd M. Zimmerman
Journal: Blood
Blood (2017) 130 (Supplement 1): 4533.
https://doi.org/10.1182/blood.V130.Suppl_1.4533.4533
Published: 2017
Journal Articles

Treatment with the Novel TOPK Inhibitor OTS514 Exhibits Potent Anti-Myeloma Activity in Pre-Clinical Models

Andrew Stefka, MS, David Johnson, Shaun Rosebeck, PhD, Jae-Hyun Park, DVM, PhD, Yusuke Nakamura, MD, Andrzej J. Jakubowiak, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4415.
https://doi.org/10.1182/blood.V130.Suppl_1.4415.4415
Published: 2017
Journal Articles

Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)

Todd Zimmerman, MD, Noopur S. Raje, Ravi Vij, Donna Reece, MD, Jesus G. Berdeja, MD, Leonor A Stephens, PhD, Kathryn McDonnell, Cara A. Rosenbaum, MD, Jagoda Jasielec, MD, Paul G Richardson, MD, Sandeep Gurbuxani, Jennifer Nam, Erica Severson, Brittany D. Wolfe, MMS, PA-C, Shaun Rosebeck, PhD, Andrew Stefka, Dominik Dytfeld, MD PhD, Kent Griffith, PhD, Andrzej Jakubowiak, MDPhD
Journal: Blood
Blood (2016) 128 (22): 675.
https://doi.org/10.1182/blood.V128.22.675.675
Published: 2016